Healthcare
Cynata Therapeutics Ltd.(CYYNF)
Live Price
Offline$0.2225
+0.00% today
1Y Change
+178.13%
Window
Jun 25, 2025 β Jun 18, 2026
- Market Cap
- $70.00M
- Revenue Growth
- -18.6%
- EPS Growth
- +15.5%
- Dividend Yield
- 0.0%
Coverage: 254 bars Β· Jun 25, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cynata Therapeutics Ltd. (CYYNF) is a Healthcare stock with a market cap of $70.00M and listed on OTC. The stock last traded around $0.22 and up 178.1% across the available one-year price window (Jun 25, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of -18.6%, EPS growth of +15.5%, a dividend yield of 0.0%. What stands out right now is revenue -18.6%, EPS +15.5%, free cash flow +11.9% with operating margin 16974.1% and ROIC -353.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CYYNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-18.6% vs +7.6% peer median
Operating Margin
Above sector median
+16974.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 26, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -18.6% and EPS is at +15.5%, with operating margin around 16974.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 31, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 26, 2026 | β | +0.0% | +0.0% | +0.0% |
2025 Jul 31, 2025 | β | +0.0% | +0.0% | +15.7% |
2025 Feb 27, 2025 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CYYNF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CYYNF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CYYNF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CYYNF and SPY.
Company Overview
Cynata Therapeutics Ltd.
OTC
Cynata Therapeutics Limited is a clinical-stage biotechnology company focused on the development and commercialization of innovative stem cell and regenerative medicine therapies. The companyβs proprietary Cymerus platform leverages induced pluripotent stem cell (iPSC) technology to produce mesenchymal stem cells for potential human therapeutic use. Cynataβs lead product candidates target a range of serious medical conditions, including graft versus host disease, osteoarthritis, and diabetic wounds, with several candidates in active clinical trials. The company also collaborates with global partners such as Fujifilm to advance manufacturing and supply capabilities. Cynata Therapeutics Limited is listed on the CHI-X Market Australia β Limit Venue, providing investors access to its shares through this alternative trading platform. Headquartered in Cremorne, Australia, and incorporated in 2003, the company plays a significant role in advancing regenerative medicine and addressing unmet clinical needs in the global healthcare sector.
- Leadership
- Dr. Kilian Kelly Ph.D.
- Street Address
- 100 Cubitt Street, Level 3
- Mailing
- Cremorne, VIC, 3121
- Region
- Cremorne, VIC, Australia
- Last Updated
- May 11, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 21.4
Growth
- Revenue
- -18.6%
- EPS
- +15.5%
- Free Cash Flow
- +11.9%
Profitability
- Gross Margin
- 253.3%
- Operating Margin
- 16974.1%
- Net Margin
- 9887.9%
- ROE
- -179.4%
- ROIC
- -353.7%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 2.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.